Cargando…
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies, representing less than 5% of all thyroid carcinomas. Τhe median survival is limited to months due to the resistance of ATC to surgery, radioiodine therapy, radiotherapy and chemotherapy. This review will cover no...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976495/ https://www.ncbi.nlm.nih.gov/pubmed/36855200 http://dx.doi.org/10.1186/s13044-023-00147-7 |